Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells

Gynecologic Oncology

Volumn 96, Issue 3, 2005, Pages 678-683

  Zhou, Rong ^a   Treeck, Oliver ^b   Horn, Felicitas ^b   Ortmann, Olaf ^b  

^a WEST CHINA UNIVERSITY OF MEDICAL SCIENCES   (China)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Apoptosis; Drug resistance; Estrogen receptor modulator; Ovarian cancer cell line; Proliferation; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR BETA; TAMOXIFEN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; WILD TYPE;

EID: 13944275572     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.11.023     Document Type: Article

References (38)

1. R. Clarke, T.C. Skaar, K.B. Bouker, N. Davis, Y.R. Lee, and J.N. Welch Molecular and pharmacological aspects of antiestrogen resistance J. Steroid Biochem. Mol. Biol. 76 2001 71 84
2. V.C. Jordan, and C.S. Murphy Endocrine pharmacology of antiestrogens as antitumor agents Endocr. Rev. 11 1990 578 610
3. R.R. Perry, Y. Kang, and B.S. Greaves Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells Ann. Surg. Oncol. 2 1995 238 245
4. J.S. Laco, P.E. Schwartz, N.J. Maclusky, D.C. Labaree, and A.J. Eisenfeld Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro Cancer Res. 44 1984 2266 2271
5. E.F. McClay, K.D. Albright, J.A. Jones, R.D. Christen, and S.B. Howell Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines Br. J. Cancer 70 1994 449 452
6. V. Smith, S. Hobbs, W. Court, S. Eccles, P. Workman, and L.R. Kelland ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin Anticancer Res. 22 2002 1993 1999
7. P. Benedetti Panici, S. Greggi, M. Amoroso, G. Scambia, F.A. Battaglia, and V. Gebbia A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a phase II study Int. J. Gynecol. Cancer 11 2001 438 444
8. C. Trope, C. Marth, and J. Kaern Tamoxifen in the treatment of recurrent ovarian carcinoma Eur. J. Cancer 36 2000 S59 S67
9. C. Marth, N. Sorheim, J. Kaern, and C. Trope Tamoxifen in the treatment of recurrent ovarian carcinoma Int. J. Gynecol. Cancer 7 1997 256 261
10. S. Mandlekar, R. Yu, T.-H. Tan, and A.-N.T. Kong Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells Cancer Res. 60 2000 5995 6000
11. C. Ferlini, G. Scambia, M. Marone, M. Distefano, C. Gaggini, and G. Ferrandina Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines Br. J. Cancer 79 1999 257 263
12. E.C. Dietze, L.E. Caldwell, S.L. Grupin, M. Mancini, and V.L. Seewaldt Tamoxifen but not 4-hydroxy-tamoxifen initiates apoptosis in normal human mammary epithelial cells by inducing mitochondrial depolarization J. Biol. Chem. 276 2001 5384 5394
13. M. Obrero, D.V. Yu, and D.J. Shapiro Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxy tamoxifen-induced programmed cell death J. Biol. Chem. 277 2002 45695 45703
14. S.J. Ahn, M.S. Yoon, S. Hyuk, W. Han, Y.D. Yoon, and J.S. Han Phospholipase c-protein kinase mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis J. Cell. Biochem. 89 2003 520 528
15. N. Nagarkatti, and B.A. Davis Tamoxifen induces apoptosis in Fas + tumor cells by upregulating the expression of Fas ligand Cancer Chemother. Pharmacol. 51 2003 284 290
16. K.-C. Choi, S.K. Kang, C.-J. Tai, N. Auersperg, and P.C.K. Leung Estradiol up-regulates antiapoptotic Bal-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells Endocrinology 142 2001 2351 2360
17. B.R. Rao, and B.J. Slotman Endocrine role in ovarian cancer Endocr.-Relat. Cancer 3 1996 309 326
18. S. Mabuchi, M. Ohmichi, A. Kimura, Y. Ikebuchi, K. Hisamoto, and E. Arimoto-Ishida Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin Endocrinology 145 2004 1302 1313
19. K.R. Geisinger, T.E. Kute, M.J. Pettenati, C.E. Welander, Y. Dennard, and L.A. Collins Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors Cancer 63 1989 280 288
20. K.R. Hande Etoposide: four decades of development of a topoisomerase II inhibitor Eur. J. Cancer 34 1998 1514 1521
21. P. Monje, and R. Boland Expression and cellular localization of naturally occurring beta estrogen receptors in uterine and mammary cell lines J. Cell. Biochem. 86 2002 136 144
22. G.B. Kristensen, and C. Trope Epthelial ovarian carcinoma Lancet 349 1997 113 117
23. W.S. Baldwin, S.W. Curtis, C.A. Cauthen, J.I. Risinger, K.S. Korach, and J.C. Barrett BG-1 ovarian cell line: an alternative model for examining estrogen-dependent growth in vitro In Vitro Cell Dev. Biol., Anim. 34 1998 649 654
24. J.W. Wilson, A.E. Wakeling, I.D. Morris, J.A. Hickman, and C. Dive MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone withdrawal and DNA damage Int. J. Cancer 61 1995 502 508
25. A. Berchuck, G.C. Rodriguez, A. Kamel, R.K. Dodge, J.T. Soper, and D.L. Clarke-Pearson Epidermal growth factor-receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer Am. J. Obstet. Gynecol. 164 1991 669 674
26. O. Alper, E.S. Bergmann-Leitner, T.A. Bennett, N.F. Hacker, K. Stromberg, and W.G. Stetler-Stevenson Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells J. Natl. Cancer Inst. 93 2001 1375 1384
27. J.M.S. Bartlett, S.P. Langdon, B.J.B. Simpson, M. Stewart, D. Katsaros, and P. Sismondi The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer Br. J. Cancer 73 1996 301 306
28. R.C. Bast Jr., L. Pusztai, B.J. Kerns, J.A. MacDonald, P. Jordan, and L. Daly Coexpression of the HER-2 gene product, p185 HER-2, and epidermal growth factor receptor, p170 EGF-R, on epithelial ovarian cancers and normal tissues Hybridoma 17 1998 313 321
29. A. Harlozinska, J.K. Bar, E. Sobanska, and M. Goluda Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms Tumour Biol. 19 1998 364 373
30. S.S. Hsieh, C. Malerczyk, A. Aigner, and F. Czubayko ErbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation Int. J. Cancer 86 2000 644 651
31. O.e. Alper, M.L.D. Santis, K. Stromberg, N.F. Hacker, Y.S. Cho-Chung, and D.S. Salomon Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells Int. J. Cancer 88 2000 566 574
32. M. Campiglio, S. Ali, P.G. Knyazev, and A. Ullrich Characteristics of EGFR family-mediated HRG signals in human ovarian cancer J. Cell. Biochem. 73 1999 522 532
33. F. Vacca, A. Bagnato, K.J. Catt, and R. Tecce Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells Cancer Res. 60 2000 5310 5317
34. A.T. Baron, E.M. Cora, J.M. Lafky, C.H. Boardman, M.C. Buenafe, and A. Rademaker Soluble epidermalgrowth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer Cancer Epidemiol., Biomarkers Prev. 12 2003 103 113
35. B.A. Goff, H.G. Muntz, B.E. Greer, H.K. Tamimi, and A.M. Gown Oncogene expression: long-term compared with short-term survival in patients with advanced epidermal ovarian cancer Obstet. Gynecol. 92 1998 88 93
36. A. Hasenburg, D.C. Fischer, X.W. Tong, A. Rojas-Martinez, C. Nyberg-Hoffman, and M. Orlowska-Volk Histologic and immunohistochemical analysis of tissue response to adenovirus mediated herpes simplex thymidine kinase gene therapy of ovarian cancer Int. J. Gynecol. Cancer 12 2002 66 73
37. J.M. Knowlden, I.R. Hutcheson, and H.E. Jones Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 2003 1032 1044
38. L.C. Murphy, E. Leygue, and Y. Niu Relationship of coregulator and estrogen receptor isoform expression to tamoxifen resistance in human breast cancer Br. J. Cancer 87 2002 1411 1416